|1.||Khazaei, Majid: 2 articles (05/2015 - 01/2015)|
|2.||Alasvand, Masoud: 2 articles (05/2015 - 01/2015)|
|3.||Rashidi, Bahman: 2 articles (05/2015 - 01/2015)|
|4.||Beck-Sickinger, Annette G: 2 articles (02/2007 - 09/2005)|
|5.||Ilebekk, Arnfinn: 2 articles (09/2006 - 10/2005)|
|6.||Nordlander, Margareta: 2 articles (09/2006 - 10/2005)|
|7.||Björkman, Jan-Arne: 2 articles (09/2006 - 10/2005)|
|8.||Shen, Li: 1 article (05/2015)|
|9.||McCutcheon, Kathleen: 1 article (05/2015)|
|10.||Raggio, Anne M: 1 article (05/2015)|
|1.||Body Weight (Weight, Body)
03/01/2014 - "Central infusion of the selective Y2R-antagonist BIIE0246 had no effect in either group, suggesting that it is not critical for the effects of RYGB on body weight under the conditions tested. "
05/01/2015 - "In a 10-week study, C57BL/6J and GLP-1 receptor null (GLP-1R KO) mice were fed control or 30% RS diet, and received daily intraperitoneal injection of either saline or PYY receptor antagonist (BIIE0246, 20 μg/kg body weight). "
08/25/2013 - "In addition, BIIE 0246 alleviated the bradycardia, but further impaired cardiac contractility in the STZ rats. "
10/01/2005 - "We found that attenuation of the bradycardia during vagal nerve stimulation was dose-dependently counteracted by BIIE0246 and that the tachycardia elicited by sympathetic stimulation remained unaffected after NPY Y2 receptor blockade. "
03/01/2012 - "The reduction in vagal bradycardia post sympathetic stimulation was partially reversed by the galanin receptor antagonist M40 after 10 min (1 μM, n=5), and completely reversed with the NPY Y(2) receptor antagonist BIIE 0246 at all time points (1 μM, n=6). "
|4.||AIDS-Related Complex (ARC)
09/01/2013 - "Food foraging, hoarding, and intake were not affected by Arc BIIE0246 microinjection in fed hamsters 1, 2, 4, and 24h post injection. "
09/01/2013 - "We microinjected BIIE0246 (antagonist) and PYY(3-36) (agonist) into the Arc to test the role of NPY-Y2Rs there on ingestive behaviors. "
05/10/2005 - "On investigation of the endogenous role of the Y2R, we found that ARC administration of BIIE0246 alone significantly increased feeding in satiated rats compared to vehicle-injected controls (0-1 h food intake: BIIE0246: 4.1 +/- 0.7 g; vs. vehicle: 1.7 +/- 0.7 g; P < 0.05), suggesting that Y2R antagonism disinhibits the NPY neuron thus stimulating feeding in otherwise satiated rats. "
05/10/2005 - "We aimed to investigate the feeding effect of PYY((3-36)) following blockade of ARC Y2R, using the specific receptor antagonist BIIE0246, in the rat. "
10/24/2007 - "The attenuation of pellet priming-induced reinstatement by systemic PYY3-36 was reversed by systemic (2 mg/kg) but not Arc (0.5 microg per side) injections of the Y2 receptor antagonist BIIE0246. "
|5.||Mood Disorders (Mood Disorder)
01/01/2010 - "The role of neuropeptide Y Y2 receptor (Y2R) in human diseases such as obesity, mood disorders, and alcoholism could be better resolved by the use of small-molecule chemical probes that are substantially different from the currently available Y2R antagonist, N-[(1S)-4-[(aminoiminomethyl)amino]-1-[[[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]amino]carbonyl]butyl]-1-[2-[4-(6,11-dihydro-6-oxo-5H-dibenz[b,e]azepin-11-yl)-1-piperazinyl]-2-oxoethyl]-cyclopentaneacetamide) (BIIE0246). "
|1.||glucagon-like peptide receptor (receptor, glucagon-like peptide)
|2.||neuropeptide Y2 receptor
|6.||Galanin Receptors (Galanin Receptor)
|9.||Morphine (MS Contin)
|10.||5-Hydroxytryptophan (5 Hydroxytryptophan)
|2.||Vagus Nerve Stimulation